Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05526599
Other study ID # 42746034
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2003
Est. completion date March 31, 2018

Study information

Verified date September 2022
Source Beijing Tsinghua Chang Gung Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective cohort study


Description:

Data source and study cohort: We conducted a retrospective cohort study using the Premier Healthcare Database (PHD, Premier Inc., Charlotte, NC), an extensive, US hospital-based, all-payer database representing approximately 20% of annual United States inpatient discharges at community and academic centers. The International Classification of Diseases, ninth revision (ICD-9), and tenth revision (ICD-10) procedure codes were used to identify patients who had undergone elective kidney cancer surgery between the 15 years of study from 2003 to 2017. The cohort was then restricted based on appropriate ICD-9 and ICD-10 diagnosis codes to ensure that surgery was performed for a kidney mass. The study cohort was also limited to adult patients (age >= 18 years), "elective" cases based on administrative codes, as well as surgery on hospital day zero or one to minimize outlier patients who could skew the surgical outcomes. Outcomes: The primary outcome of this study was the 90-day complication rate. Complication rates were based on the Clavien-Dindo classification of surgical complications and divided into four categories: no complications, minor complications (Clavien grades 1, 2), and non-fatal major complications (Clavien grades 3, 4), and mortality (Clavien grade 5). Clinical systems also categorized complications (bleeding, cardiac, endocrine, gastrointestinal, infection, neurology, pulmonary, renal, soft tissue, urologic, venous thromboembolism) using Health Care Cost and Utilization Project Clinical Classification Software Level II or III designations; of note, the category for "surgical" complications was excluded given that all complications captured in this analysis are considered surgical complications. Secondary outcomes included patient disposition, length of hospital stay, and readmission rate.


Recruitment information / eligibility

Status Completed
Enrollment 106752
Est. completion date March 31, 2018
Est. primary completion date March 31, 2018
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Surgery was performed for a kidney mass. 2. age >= 18 years 3. "elective" cases 4. Surgery was performed on the day0 or day1 after administration. Exclusion Criteria: 1. ICD codes are not available. 2. Missing value of the primary outcomes and exposure.

Study Design


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Beijing Tsinghua Chang Gung Hospital Brigham and Women's Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary surgical complications Complication rates were based on the Clavien-Dindo classification of surgical complications and divided into four categories: no complications, minor complications (Clavien grades 1, 2), and non-fatal major complications (Clavien grades 3, 4), and mortality (Clavien grade 5). 90 days after surgery
Secondary patient disposition patient disposition was divided into home and none home such as skilled nursing or rehabilitation facility 90 days after surgery
Secondary readmission rates readmission was defined as readmitted into the hospital for any reason 90 days after surgery
See also
  Status Clinical Trial Phase
Completed NCT00678392 - Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Phase 3
Not yet recruiting NCT03129724 - Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib N/A
Terminated NCT01413607 - The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Phase 4
Terminated NCT00091611 - Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer Phase 1
Terminated NCT02439008 - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response N/A
Completed NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Recruiting NCT05184504 - Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Terminated NCT01712685 - Imaging Studies of Kidney Cancer Using 18F-VM4-037 Phase 2
Terminated NCT00816686 - A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer Phase 1
Completed NCT00537056 - Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI N/A
Completed NCT00076011 - Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT00226980 - A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03062410 - Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma N/A
Completed NCT02924922 - Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A